RenovoRx TAMP Therapy Cuts Tumor Activity After Eight Gemcitabine Cycles, Hits $1.1M Sales
RenovoRx presented at the 2026 SIR meeting clinical data showing eight cycles of intra-arterial gemcitabine via its TAMP platform reduced FDG PET/CT tumor activity in locally advanced pancreatic cancer with minimal systemic toxicity. The company also reported $1.1 million in RenovoCath sales in its first commercial year and repeat orders.
1. Clinical Data Presentation
At the 2026 Society of Interventional Radiology Annual Scientific Meeting, RenovoRx’s TAMP platform delivered eight cycles of intra-arterial gemcitabine using the RenovoCath device in locally advanced pancreatic cancer patients, aiming to enhance local drug penetration and overcome hypovascular tumor stroma.
2. Metabolic Imaging Outcomes
FDG PET/CT imaging post-treatment showed notable reductions in tumor FDG avidity despite minimal anatomical changes, indicating early therapeutic response and supporting TAMP’s potential to reduce systemic toxicity compared to intravenous chemotherapy.
3. Commercial Performance
In its first full commercial year, RenovoRx generated approximately $1.1 million in RenovoCath sales, with several high-volume National Cancer Institute-designated centers initiating new and repeat orders, demonstrating early market traction.
4. Ongoing Phase III Trial
RenovoRx continues the Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine delivered via RenovoCath (IAG) for LAPC, leveraging these clinical findings to inform regulatory discussions and potential combination product approval.